A preprint study has reported that people who used “gray-market” compounded retatrutide experienced less weight loss over as long as 12 months than participants in clinical trials of the investigational drug. MedPage Today summarized the finding in its August 25, 2026 endocrinology news roundup, linking to the study manuscript on Preprints.org. The manuscript has not undergone peer review, so its methods and conclusions should be treated as preliminary.
The comparison is important, but it does not establish that a particular commercial product is safe or that gray-market retatrutide is equivalent to the medicine being studied by Eli Lilly. “Compounded retatrutide” sold outside a regulated trial may differ in identity, concentration, sterility, storage, and handling. People may also use different doses, schedules, or injection techniques than those specified in a clinical protocol. Those differences make a direct comparison with trial results difficult and mean that a lower average result cannot be interpreted as a reliable estimate of what any individual product will do.
Why clinical-trial results cannot be transferred to online vials
Retatrutide (LY3437943) is a once-weekly investigational GIP, GLP-1, and glucagon receptor agonist. The well-known weight-loss figures for retatrutide come from controlled research in which the product, dose escalation, eligibility criteria, follow-up, and adverse-event monitoring are defined in advance. An online vial labelled retatrutide has no comparable assurance. It may be incorrectly labelled, diluted, contaminated, or contain a different substance altogether.
The preprint therefore adds a useful caution to the public discussion: even when people believe they are taking “reta,” real-world outcomes may not resemble the results reported in pharmaceutical trials. It should not be used to calculate a dose, validate a supplier, or support self-treatment. It also does not replace peer-reviewed evidence or a regulator’s assessment of quality, safety, and effectiveness.
What this means for Canadians
Retatrutide remains unapproved by Health Canada and is not available for routine pharmacy sale in Canada. Canadians should not order it from peptide websites, social-media sellers, or messaging groups, and should not assume that a “research use only” label makes an injectable product safe for personal use. Recent reports of counterfeit products and serious illness linked to unregulated vials reinforce the distinction between trial-supplied retatrutide and products sold through informal channels.
Legitimate access is limited to an authorized clinical trial or, in appropriate circumstances, a physician-led request through Health Canada’s Special Access Programme. Anyone who has used an unregulated injectable and feels unwell should seek medical care and tell the clinician exactly what was taken.
Sources
- MedPage Today: “Gray Market” Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings (August 25, 2026)
- Preprints.org: manuscript 202608.1193 (preprint; not peer reviewed)
- Health Canada: Special Access Programme — Drugs